RxDoctor Payments Data

Natalia Natovich, MD

Internal Medicine · Brooklyn, NYNPI 1750324117

Payments from drug & device makers

$678in general payments, 2019–2025

Across 27 payments — averaging $25.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$145
  • Merck$121
  • AbbVie$120
  • Astellas Pharma US Inc$54
  • Otsuka America Pharmaceutical, Inc.$51
  • Lundbeck LLC$50
  • plus $137 from 5 others

What the payments were for

  • Food & beverage$678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$678 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$79,169
Medicare patients
35
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase15$45,858
CreonLipase/Protease/Amylase16$36,656
Diclofenac Sodium61$28,743
PancreazeLipase/Protease/Amylase16$23,014
EliquisApixaban34$21,917
JanuviaSitagliptin Phosphate20$15,555
MyrbetriqMirabegron25$11,838
RestasisCyclosporine18$11,403
OzempicSemaglutide12$11,089
LinzessLinaclotide22$11,017
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,256
VascepaIcosapent Ethyl22$7,669
JentaduetoLinagliptin/Metformin Hcl14$7,271
ZetiaEzetimibe16$6,288
DexilantDexlansoprazole15$4,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Restasis, Linzess, Synthroid$120$60,42684 claims
Vivus LLCPancreaze$20$23,01416 claims
MerckJanuvia$121$15,55520 claims
Astellas Pharma US IncMyrbetriq$54$11,83825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →